Parkman Healthcare Partners LLC Altimmune, Inc. Transaction History

Parkman Healthcare Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$3.94 - $11.77 $985,665 - $2.94 Million	250,169 Added 80.81%	559,755 $6.55 Million
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $272,060 - $435,758	46,112 Added 17.5%	309,586 $1.89 Million
Q4 2021 Feb 11, 2022	BUY	$8.69 - $12.48 $768,839 - $1.1 Million	88,474 Added 50.56%	263,474 $2.41 Million
Q3 2021 Nov 12, 2021	SELL	$8.43 - $16.81 $210,750 - $420,249	-25,000 Reduced 12.5%	175,000 $1.98 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $1.97 Million - $3.29 Million	200,000 New	200,000 $1.97 Million
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $1.27 Million - $2.43 Million	-100,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $784,000 - $1.42 Million	100,000 New	100,000 $1.13 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.